8-K: Achieve Life Sciences Announces Positive 2023 Results and Secures Funding for Cytisinicline Development

Achieve Life Sciences reported its 2023 financial results, highlighted by a significant funding round and progress in the development of cytisinicline for smoking cessation.

Summary

• Achieve Life Sciences announced its financial results for the fourth quarter and year ended December 31, 2023, along with a corporate update.
• The company reached an agreement with the FDA on long-term cytisinicline exposure requirements, paving the way for a New Drug Application (NDA) submission anticipated in the first half of 2025.
• A substantial equity financing of up to $124.2 million was completed, including $60.0 million in upfront gross proceeds and up to an additional $64.2 million upon exercise of milestone-driven warrants.
• Data from Phase 3 ORCA-2 and ORCA-3 trials, and Phase 2 ORCA-V1 trial were presented at the Society for Research on Nicotine and Tobacco (SRNT) conference.
• The company's cash position was $15.6 million as of December 31, 2023, which would have been $71.8 million on a pro forma basis after the February 2024 equity financing.
• Total operating expenses for 2023 were $27.3 million, and the net loss was $29.8 million.
• The company plans to initiate the ORCA-OL open label exposure trial in the second quarter of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful funding round, positive clinical trial results, and progress with the FDA. The company appears to be on track to achieve its goals.

Positives

• The agreement with the FDA on long-term exposure requirements significantly de-risks the NDA submission process.
• The successful equity financing provides the company with a strong financial runway to advance cytisinicline development.
• The positive clinical trial results for both smoking and vaping cessation highlight the potential of cytisinicline.
• High rates of user satisfaction and recommendation for cytisinicline suggest strong market potential.
• The company has a clear plan to initiate the ORCA-OL open label exposure trial in the second quarter of 2024.

Negatives

• The company reported a net loss of $29.8 million for the year ended December 31, 2023.
• Operating expenses were $27.3 million for the year ended December 31, 2023.
• The company's cash position before the recent financing was relatively low at $15.6 million.

Risks

• The company's success is heavily dependent on the successful development and regulatory approval of cytisinicline.
• There is a risk that cytisinicline may not demonstrate the expected benefits or receive regulatory approval.
• The company may need to secure additional financing in the future if the milestone-driven warrants are not exercised.
• Changes in the smoking cessation landscape could impact the company's business strategy.
• The company faces risks related to macroeconomic conditions, including inflation and instability in the global banking sector.

Future Outlook

Achieve expects the proceeds from the recent financing to fund the development of cytisinicline into 2026 and through potential FDA approval. The company anticipates submitting an NDA in the first half of 2025.

Management Comments

• 2023 marked a significant turning point for Achieve as we accomplished several key milestones.
• We are appreciative of the strong support and confidence from our stakeholders, including new investors who participated in the recent financing and smoking cessation opinion leaders who share in our enthusiasm for cytisinicline's potential.

Industry Context

The announcement comes amid a growing focus on smoking and vaping cessation treatments, with a significant market opportunity for effective solutions. The company is positioning cytisinicline as a potential alternative to existing treatments, addressing both smoking and e-cigarette addiction.

Comparison to Industry Standards

• The 69% quit rate reported in the Phase 3 trials is competitive with other smoking cessation treatments, such as varenicline and bupropion, which have shown quit rates ranging from 20% to 40% in clinical trials.
• The positive results in vaping cessation are particularly noteworthy, as there are currently no FDA-approved treatments specifically for e-cigarette addiction, giving Achieve a potential first-mover advantage.
• The company's ability to secure $124.2 million in funding is a strong indicator of investor confidence in the potential of cytisinicline, which is comparable to other late-stage biotech companies focused on novel therapeutics.

Stakeholder Impact

• Shareholders are positively impacted by the successful funding round and progress in cytisinicline development.
• Potential customers (smokers and vapers) may benefit from a new and effective treatment option.
• Employees may benefit from the company's growth and success.

Next Steps

• Achieve plans to initiate the ORCA-OL open label exposure trial in the second quarter of 2024.
• The company anticipates submitting an NDA in the first half of 2025.

Key Dates

Keywords

cytisinicline, smoking cessation, nicotine dependence, vaping cessation, FDA, clinical trials, ORCA-2, ORCA-3, ORCA-V1, NDA, equity financing, pharmaceutical